Can I Take Vitamin D with Enclomiphene Citrate?

How Enclomiphene Citrate Works

Enclomiphene citrate is the trans-isomer of clomiphene. It binds estrogen receptors in the hypothalamus and pituitary, blocking the negative-feedback signal that estrogen normally sends to suppress gonadotropin-releasing hormone (GnRH) pulses. The result is a coordinated rise in luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn drives the Leydig cells of the testes to produce more endogenous testosterone.

Why Enclomiphene Is Preferred Over Clomiphene for Some Men

Clomiphene is a racemic mixture of the enclomiphene (trans) and zuclomiphene (cis) isomers. Zuclomiphene has a much longer half-life, roughly 30 days, and carries partial estrogen-agonist activity that may blunt the gonadotropin response over time. Enclomiphene, with a half-life closer to 10 hours, avoids that problem. A phase 3 trial by Kim et al. (2013, N=124) showed enclomiphene 12.5 mg/day restored morning testosterone to normal-range values in 79% of men with secondary hypogonadism at 3 months while preserving spermatogenesis, a benefit not reliably seen with exogenous testosterone therapy. [1]

Current Regulatory and Prescribing Status

The FDA has not approved enclomiphene as a standalone product for male hypogonadism as of 2025. Prescribers use it off-label, often compounded, at doses of 12.5 to 25 mg/day. Because it is off-label, the Endocrine Society's 2018 guidelines on male hypogonadism note that SERMs including clomiphene and its isomers "may be considered for men who wish to preserve fertility," acknowledging limited long-term safety data. [2]

What Vitamin D Does in the Male Endocrine System

Vitamin D is not simply a bone mineral. The vitamin D receptor (VDR) is expressed in Leydig cells, Sertoli cells, and the pituitary gland, positioning calcitriol (the active 1,25-dihydroxyvitamin D form) as a direct participant in male reproductive physiology rather than a bystander.

Vitamin D and Testosterone: What the Data Show

A cross-sectional analysis of 2,299 men in the European Male Aging Study found that 25(OH)D levels below 20 ng/mL were independently associated with lower total testosterone after adjusting for age, BMI, and season. [3] A 12-month randomized controlled trial by Pilz et al. (2011, N=165) reported that men receiving 3,332 IU/day of vitamin D3 had a mean testosterone increase of 25.2% compared with placebo (from 10.7 nmol/L to 13.4 nmol/L), a between-group difference of P<0.001. [4]

The mechanism proposed in that trial centers on VDR-mediated transcription of the CYP17A1 and StAR genes inside Leydig cells, both of which regulate steroidogenesis. Calcitriol may also reduce sex hormone-binding globulin (SHBG) synthesis in the liver, increasing free testosterone availability, though this effect remains under active investigation. [4]

Vitamin D Deficiency Is Disproportionately Common in Men Seeking TRT or Enclomiphene

Data from the National Health and Nutrition Examination Survey (NHANES) show that approximately 41% of U.S. Adults have serum 25(OH)D below 20 ng/mL. [5] Among men presenting for testosterone-related care, rates of insufficiency (<30 ng/mL) can approach 70% in some cohorts, particularly in northern latitudes and among men with obesity, given that adipose tissue sequesters vitamin D. Men on enclomiphene for secondary hypogonadism often share these same metabolic risk factors, making baseline 25(OH)D testing practically worthwhile.

The Pharmacokinetic Picture: Do Enclomiphene and Vitamin D Interact?

Short answer: no meaningful pharmacokinetic interaction has been identified.

Metabolic Pathways

Enclomiphene is metabolized primarily by hepatic CYP3A4 and, to a lesser extent, CYP2D6. [6] Vitamin D3 (cholecalciferol) undergoes 25-hydroxylation mainly via CYP2R1 and CYP27A1 in the liver, then 1-alpha-hydroxylation by CYP27B1 in the kidney to form calcitriol. [7] These pathways do not share the same primary enzyme. Neither compound is a potent inhibitor or inducer of the other's primary CYP isoform at therapeutic doses, so plasma levels of enclomiphene should not be materially affected by vitamin D supplementation and vice versa.

Protein Binding

Enclomiphene is highly protein-bound (greater than 98%), primarily to albumin and alpha-1-acid glycoprotein. Vitamin D metabolites bind to vitamin D-binding protein (GC-globulin). These are distinct binding proteins, so displacement interactions are not a recognized concern. [6][7]

Absorption Timing

Enclomiphene is typically taken once daily, often in the morning. Vitamin D3 is fat-soluble and absorbs best when taken with a meal containing dietary fat. Neither compound requires separation from the other for absorption reasons. A patient who takes both at breakfast with a fat-containing meal obtains optimal absorption of vitamin D without any pharmacokinetic concern for enclomiphene. [7]

Pharmacodynamic Considerations: Where the Two Compounds Interact Indirectly

Even without a direct pharmacokinetic interaction, the two compounds operate in overlapping physiologic territory, specifically the hypothalamic-pituitary-gonadal (HPG) axis. Understanding this overlap helps set appropriate expectations.

Additive Support of Testosterone Production

Enclomiphene removes estrogenic brake pressure on GnRH release, pushing LH higher. Vitamin D, via VDR signaling in Leydig cells, may support the downstream steroidogenic machinery that responds to that LH signal. In theory, the two mechanisms are additive rather than antagonistic. A 2015 observational analysis published in the Journal of Clinical Endocrinology and Metabolism found that men with higher 25(OH)D had a more favorable LH-to-testosterone ratio, suggesting better Leydig cell sensitivity, though this relationship has not yet been tested in a trial specifically involving enclomiphene. [8]

Calcium and Parathyroid Hormone

One pharmacodynamic consideration worth tracking is the calcium-PTH axis. Vitamin D increases intestinal calcium absorption and suppresses PTH. Enclomiphene has no known direct effect on calcium or PTH. Still, very high vitamin D doses (above 4,000 IU/day sustained) can produce hypercalcemia in susceptible individuals. Men with a history of kidney stones, granulomatous conditions (sarcoidosis, tuberculosis), or primary hyperparathyroidism face elevated risk and should have serum calcium and 25(OH)D monitored before and during supplementation. [9]

Bone Density: A Shared Benefit

Secondary hypogonadism is associated with reduced bone mineral density. Enclomiphene raises endogenous testosterone, which supports bone remodeling. Adequate vitamin D and calcium intake are foundational to that same goal. The National Osteoporosis Foundation recommends 1,000 to 1,200 mg/day of elemental calcium alongside 800 to 1,000 IU/day of vitamin D for general skeletal health, with higher doses guided by blood levels. [10] Men on enclomiphene who are also vitamin D deficient may be missing a significant non-hormonal contributor to bone health.

Dosing Guidance for Vitamin D While on Enclomiphene

No clinical trial has co-dosed enclomiphene and vitamin D to determine an optimal combined protocol. The guidance below reflects established vitamin D dosing standards applied to the enclomiphene population.

Baseline Testing

A 25-hydroxyvitamin D (25(OH)D) level should be obtained before starting supplementation. This is a standard serum test available through any commercial lab. The Endocrine Society defines:

• Deficiency: <20 ng/mL
• Insufficiency: 20 to 29 ng/mL
• Sufficiency: 30 to 100 ng/mL
• Potential toxicity: consistently above 150 ng/mL

Repletion Versus Maintenance Dosing

For men with deficiency (<20 ng/mL), the Endocrine Society recommends 50,000 IU of vitamin D2 or D3 once weekly for 8 weeks, followed by reassessment and a maintenance dose of 1,500 to 2,000 IU/day. [9] For men with insufficiency (20 to 29 ng/mL), a daily dose of 1,500 to 2,000 IU is typically sufficient without a loading phase. Vitamin D3 (cholecalciferol) raises 25(OH)D levels roughly 25 to 40% more effectively than D2 (ergocalciferol) at equivalent doses, making D3 the preferred form. [11]

Upper Safety Limit

The Tolerable Upper Intake Level (UL) set by the National Academy of Medicine is 4,000 IU/day for adults. Doses above this threshold should only be used under medical supervision with periodic 25(OH)D and serum calcium checks every 3 months. [12]

Suggested Monitoring Schedule for Men on Enclomiphene Plus Vitamin D

The following monitoring cadence integrates enclomiphene-specific labs with vitamin D-specific markers:

| Timepoint | Labs | |-----------|------| | Baseline (before starting) | Total T, LH, FSH, SHBG, prolactin, CBC, CMP, 25(OH)D, serum calcium | | 6 to 8 weeks | Total T, LH, FSH, 25(OH)D (if repletion loading dose used) | | 3 months | Total T, LH, FSH, 25(OH)D, serum calcium, CMP | | 6 months | Full baseline panel repeat | | Annually | All of the above, plus DEXA if osteopenia history |

This schedule allows your prescriber to see whether enclomiphene is raising LH and testosterone appropriately, whether your 25(OH)D has reached the target range, and whether calcium is staying within normal limits.

Special Populations and Cautions

Obesity and Vitamin D Sequestration

Men with a BMI above 30 often need higher vitamin D doses to reach the same serum 25(OH)D level because adipose tissue sequesters the fat-soluble vitamin. A body-weight-based dosing approach of 6,000 to 10,000 IU/day may be required temporarily in obese men with severe deficiency, always with monitoring. This is also the group most likely to present with secondary hypogonadism driven by excess aromatase activity in adipose tissue, making the combination of enclomiphene and adequate vitamin D status particularly relevant. [9]

Renal Impairment

Men with chronic kidney disease (CKD stages 3 to 5) have impaired CYP27B1-mediated conversion of 25(OH)D to calcitriol. Standard cholecalciferol supplementation may be insufficient, and activated vitamin D analogs (calcitriol, paricalcitol) may be needed instead. Enclomiphene itself is not renally cleared to a significant degree, but any coexisting CKD warrants nephrology input before high-dose supplementation. [7]

Drug Interactions Involving Vitamin D (Not Enclomiphene-Specific)

Certain medications reduce vitamin D absorption or metabolism independent of enclomiphene:

• Orlistat and cholestyramine reduce fat-soluble vitamin absorption including vitamin D
• Rifampin and anticonvulsants (phenytoin, phenobarbital) induce CYP enzymes that accelerate vitamin D catabolism
• Thiazide diuretics combined with high-dose vitamin D increase the risk of hypercalcemia

If a patient is on any of these medications alongside enclomiphene, vitamin D dosing should be reviewed by the prescriber rather than self-managed.

What HealthRX Clinicians Look for in Practice

Men presenting to HealthRX for enclomiphene evaluation frequently arrive with suboptimal 25(OH)D levels. The clinical picture is not just "low testosterone." It is a cluster of hormonal and micronutrient gaps that often require parallel correction.

A HealthRX physician reviewing a 38-year-old man started on enclomiphene 12.5 mg/day would typically check 25(OH)D at baseline. If that value comes back at 18 ng/mL, the clinical recommendation would be to start vitamin D3 50,000 IU/week for 8 weeks, then shift to 2,000 IU/day maintenance, with a follow-up 25(OH)D and calcium at the 8-week testosterone recheck. This approach treats both the SERM-mediated hormonal pathway and the micronutrient environment in which those hormonal signals operate.

The Endocrine Society's 2011 vitamin D clinical practice guideline states: "We suggest that all adults who are obese or are taking anticonvulsant medications, glucocorticoids, antifungals such as ketoconazole, and medications for AIDS be given at least two to three times more vitamin D for their age group to satisfy their body's vitamin D requirement." [9] While that statement targets specific drug classes, the principle of individualized dosing guided by blood levels applies broadly.

Frequently Asked Questions